Six‐month trial of on‐demand rabeprazole 10 mg maintains symptom relief in patients with non‐erosive reflux disease

Omeprazole 10 Milligrams Once Daily, Omeprazole 20 Milligrams Once Daily, or Ranitidine 150 Milligrams Twice Daily, Evaluated as Initial Therapy for the Relief of Symptoms of Gastro-oesophageal Reflux Disease in General Practice

1997 • 294 citations

Nonerosive Reflux Disease— Current Concepts and Dilemmas

2001 • 270 citations

Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents

1997 • 258 citations

On demand therapy with omeprazole for the long‐term management of patients with heartburn without oesophagitis—a placebo‐controlled randomized trial

1999 • 203 citations

Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients.

1997 • 189 citations

Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months

2001 • 187 citations

A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1998 • 179 citations

Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux disease

1999 • 161 citations

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

2002 • 157 citations

Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease

2000 • 140 citations

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

2003 • 136 citations

Factors influencing compliance in long-term proton pump inhibitor therapy in general practice.

1999 • 126 citations

Natural history of gastro-oesophageal reflux disease without oesophagitis.

1991 • 122 citations

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.

1998 • 120 citations

A Cost-Effectiveness Analysis of Prescribing Strategies in The Management of Gastroesophageal Reflux Disease

2000 • 116 citations

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

2002 • 115 citations

Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis

2002 • 90 citations

Goals of Therapy and Guidelines for Treatment Success in Symptomatic Gastroesophageal Reflux Disease Patients

2003 • 75 citations

Rabeprazole, 20 mg Once Daily or 10 mg Twice Daily, Is Equivalent to Omeprazole, 20 mg Once Daily, in the Healing of Erosive Gastrooesophageal Reflux Disease

2000 • 71 citations

Immunopathogenetic and therapeutic aspects of autoimmune hepatitis

2002 • 69 citations

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects

2002 • 68 citations

Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects

2003 • 21 citations

Review article: rabeprazole’s tolerability profile in clinical trials

1999 • 16 citations

Cited By (0)

Loading...